Latest News

BerGenBio plans IPO and partners with MSD

To activate the Axl kinase and transmit its signal to the cell nucleus, the GAS6 ligand has to bind externally and the energy carrier ATP (green) internally. Inhibitors (orange) prevent transmission of the signal, © MPI for Biochemistry


by tg

Norwegian BerGenBio ASA said it will go public at Oslo Børs and partnered with Merck & Co. for conducting Phase II combination studies of its oral Axl kinase blocker BGB324 with Merck’s PD-1 inhibitor pembrolizumab in lung cancer patients.

The IPO, underwritten by ABG Sundal Collier, Arctic Securities and DNB Markets, includes a public offering to institutional and retail investors in Norway and Sweden, and a private placement to certain institutional investors internationally.

BerGenBio’s lead candidate BGB324 (formerly R-428), licensed from Rigel Pharmaceuticals in 2010, has passed Phase Ib testing in acute myeloid leukemia (AML), myeloid dysplastic syndrome (MDS), and non-small cell lung cancer (NSCLC, in combination with erlonitib) patients. On the day of the IPO announcement, BerGenBio additionally said it will start two collaborative Phase II combination studies of BGB324 with Merck & Co’s PD-1 checkpoint inhibitor pembrolizumab this year in patients with adenocarcinoma (NSCLC) and and triple-negative breast cancer (TNBC). The clinical trials will be sponsored by BerGenBio while Merck will provide the trial with Keytruda. The rights to the study results will be shared. Financial details were not disclosed. Preclinical data from 2015 indicate that BGB324 showed enhanced tumour clearance, survival and tumour infiltration of cytotoxic T lymphocytes compared with checkpoint inhibition (CTLA-4, PD1) alone.

Axl kinase promotes cancer cell migration, epithelial-mesenchymal transition (EMT) and tumour cell proliferation as well as therapy resistance. The protein is overexpressed in the membranes of 60% of lung cancers, highly invasive breast cancers, and pancreatic cancer as well as in AML, where it serves as independent prognostic marker. Additionally, several studies suggest that overexpression of AXL may result in resistance to both targeted therapies and conventional chemotherapy in different models, such as lung cancer, breast cancer resistant to EGFR inhibition, esophageal carcinoma, gastrointestinal stromal tumours, and AML. 

Besides its selective Axl kinase inhibitor, the Norwegian company also has an anti-Axl kinase antibody and an antibody drug conjugate (ADC) under preclinical development. Treatment responders are set to be stratified prior to therapy by a companion diagnostics test that measures Axl kinase expression.

Roche’s Tecentriq prolongs OS in SCLC

According to results from the IMpower133 Phase III trail, presented at the world cancer conference on lung cancer (WCLC) and published in the New...

Getting ready for Brexit

Hard Brexit or soft Brexit – however the UK will leave the European Union next year, the process is sure to cause some disruption. Now, pharma...

Switch for osteoporosis and obesity

The research group of Anja Saalbach at University of Leipzig, Germany, reported that altering levels of the Thy-1 protein disrupts the...

EU set to speed up switch to bioeconomy by new action plan

Research Commissioner Carlos Moedas said in Brussels that much has been achieved in the past six years since the EC established the bioeconomy...

Sanofi preparing label extension for dupilumab

According to data presented at the 27th European Academy of Dermatology and Venereology (EADV) Congress in Paris, the inhibitor of type 2...

Urovant Sciences licenses OAB gene therapy

hMaxi-K adds to the public Swiss company’s lead product candidate in OAB, vibegron, an oral, once-daily, small molecule beta-3 agonist,...

BIOSPAIN expanding

With more than 35+ sessions the bi-annual three-day-event (25 to 27 September 2018), which attracted up to 1,500 biotech professionals, demonstrated...